Aimmune Therapeutics (AIMT) Downgraded to “Sell” at BidaskClub

Share on StockTwits

Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Thursday.

AIMT has been the subject of several other research reports. ValuEngine cut shares of Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aimmune Therapeutics in a report on Friday, November 23rd. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 29th. Goldman Sachs Group began coverage on shares of Aimmune Therapeutics in a report on Thursday, December 13th. They issued a “neutral” rating and a $32.00 target price for the company. Finally, Credit Suisse Group set a $40.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Wednesday, December 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $46.75.

NASDAQ AIMT opened at $21.48 on Thursday. Aimmune Therapeutics has a 52 week low of $20.94 and a 52 week high of $36.12. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -5.85 and a beta of -0.11.

Several institutional investors have recently modified their holdings of AIMT. Bank of New York Mellon Corp boosted its holdings in shares of Aimmune Therapeutics by 9.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 171,766 shares of the biotechnology company’s stock valued at $4,619,000 after buying an additional 14,283 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Aimmune Therapeutics by 32.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,251 shares of the biotechnology company’s stock valued at $690,000 after buying an additional 6,215 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Aimmune Therapeutics by 20.3% in the 3rd quarter. American Century Companies Inc. now owns 145,363 shares of the biotechnology company’s stock valued at $3,966,000 after buying an additional 24,531 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Aimmune Therapeutics by 6.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 145,966 shares of the biotechnology company’s stock valued at $3,982,000 after buying an additional 9,289 shares in the last quarter. Finally, Jennison Associates LLC boosted its holdings in shares of Aimmune Therapeutics by 0.8% in the 3rd quarter. Jennison Associates LLC now owns 432,976 shares of the biotechnology company’s stock valued at $11,812,000 after buying an additional 3,442 shares in the last quarter. Institutional investors and hedge funds own 73.44% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Further Reading: What Factors Can Affect Return on Equity?

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.